Presentation and Poster Include Previously Announced Results of Cohort A of SIGNAL Trial
ROCHESTER, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces details of a presentation and poster on November 8th and 9th at the Huntington Study Group’s 25th Annual Meeting: HSG 2018 in Houston, Tex.
Both the presentation and the poster outlined the action of VX15 (pepinemab) anti-semaphorin 4D antibody as ameliorating the neurodegenerative processes in preclinical and clinical studies. The company has completed and analyzed data from Cohort A the SIGNAL trial, and expects to complete enrollment in Cohort B, a randomized, double-blind, placebo-controlled phase 2 study of VX15 (pepinemab) in approximately 260 patients with Huntington’s Disease. Endpoints include quantitative cognitive and motor assessments and functional and patient-reported outcomes, as well as imaging measures of change in energy metabolism and volumetric MRI in defined brain regions.
The first cohort enrolled 36 patients, with all subjects either crossing over to or continuing with VX15 (pepinemab) treatment after 6 months. To date, evaluated patients showed no concerning safety signals and biomarker imaging results have been encouraging. In addition to safety and imaging, Cohort A data following 11 months of treatment and three months of safety follow up provided the company with important guidance in the design of the second cohort of the trial.
“As we continue enrollment into the second cohort of the SIGNAL trial, we are heartened by the potential for VX15 (pepinemab) in treating Huntington’s Disease, a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain in more than 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease,” commented Maurice Zauderer, CEO of Vaccinex, Inc. “We look forward to providing updates on our progress in the trial as they become available.”
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in Rochester, New York.
About the Huntington Study Group
The Huntington Study Group (HSG), which was formed in 1993, is the world’s first HD cooperative therapeutic research organization. Today, HSG is a world leader in facilitating high quality clinical research trials and studies that bring us closer to finding more effective treatments for HD and reducing the burden of HD for families affected by the disease. HSG is an organization of compassionate professionals dedicated to finding treatments that make a difference, providing rigorous care initiatives, and improving the quality of life and outcomes for HD families. How? By bringing together families, medical professionals, clinical researchers, HD advocacy groups, and sponsors to raise awareness of HD, share knowledge and best practices, and develop innovative treatments.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements may involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab (VX15), and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our prospectus for our initial public offering dated August 9, 2018, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended.